Ben Bakondi co-developed a novel CRISPR-based gene editing strategy to treat inherited retinal disease as a postdoc in Cedars-Sinai’s Regenerative Medicine Institute. Pre-clinical studies are underway to demonstrate long-term safety and efficacy. Dr. Bakondi holds a PhD in Cell & Molecular Biology from UVM College of Medicine and a Master’s degree in Biotechnology from Columbia University.